ANN ARBOR STAGE III MARGINAL ZONE LYMPHOMA
Clinical trials for ANN ARBOR STAGE III MARGINAL ZONE LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III MARGINAL ZONE LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III MARGINAL ZONE LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a new drug called parsaclisib added to standard chemotherapy (R-CHOP) for people with newly diagnosed, high-risk diffuse large B-cell lymphoma. About 50 adults will take part to find the best dose and see if the combination is safe and works better than standard …
Matched conditions: ANN ARBOR STAGE III MARGINAL ZONE LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
New drug cocktail shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of three drugs—ALX148, rituximab, and lenalidomide—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the best dose and see how well the combo controls the cancer. About 47 adults w…
Matched conditions: ANN ARBOR STAGE III MARGINAL ZONE LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 02, 2026 11:57 UTC